EUVIMEDEUVIMED entdecken
Crossref

Inhibition of the RBMS1/PRNP axis improves ferroptosis resistance‐mediated oxaliplatin chemoresistance in colorectal cancer

Yini Xu, Jingpeng Hao, Qiang Chen, Yafei Qin, Hong Qin, Shaohua Ren, Chenglu Sun, Yanglin Zhu, Bo Shao, Jingyi Zhang, Hao Wang

Molecular Carcinogenesis · 2024-02 · 63 (2) · 224-237

DOI: 10.1002/mc.23647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 20.10.2023. Verfasst von Yini Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Ferroptosis, Colorectal Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Tianjin, Science and Technology Project of Tianjin Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The majority of patients with advanced colorectal cancer have chemoresistance to oxaliplatin, and studies on oxaliplatin resistance are limited. Our research showed that RNA‐binding motif single‐stranded interacting protein 1 (RBMS1) caused ferroptosis resistance in tumor cells, leading to oxaliplatin resistance. We employed bioinformatics to evaluate publically accessible data sets and discovered that RBMS1 was significantly upregulated in oxaliplatin‐resistant colorectal cancer cells, in tandem with ferroptosis suppression. In vivo and in vitro studies revealed that inhibiting RBMS1 expression caused ferroptosis in colorectal cancer cells, restoring tumor cell sensitivity to oxaliplatin. Mechanistically, this is due to RBMS1 inducing prion protein translation, resulting in ferroptosis resistance in tumor cells. Validation of clinical specimens revealed that RBMS1 is similarly linked to tumor development and a poor prognosis. Overall, RBMS1 is a potential therapeutic target with clinical translational potential, particularly for oxaliplatin chemoresistance in colorectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisColorectal NeoplasmsHumansOxaliplatinDrug Resistance, NeoplasmCell Line, TumorDNA-Binding ProteinsRNA-Binding ProteinsPrion Proteins

Stichwörter der Autor:innen

RNA-binding motif single-stranded interacting protein 1colorectal cancerferroptosisoxaliplatin resistance

Substanzen

OxaliplatinRBMS1 protein, humanDNA-Binding ProteinsRNA-Binding ProteinsPRNP protein, humanPrion Proteins

Autor:innen und Institutionen

  • Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China.
  • Tianjin General Surgery Institute, Tianjin, China.
  • Department of Anorectal Surgery, Tianjin Medical University Second Hospital, Tianjin, China.
  • Department of Vascular Surgery, Henan Provincial People's Hospital, The Affiliated People's Hospital of Zhengzhou University, Zhengzhou, China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Tianjin
  • Science and Technology Project of Tianjin Health Commission
  • Tianjin Key Medical Discipline (Specialty) Construction Project

Zitieren

APA

Xu, Y., Hao, J., Chen, Q., Qin, Y., Qin, H., Ren, S., Sun, C., Zhu, Y., Shao, B., Zhang, J., & Wang, H. (2024). Inhibition of the RBMS1/PRNP axis improves ferroptosis resistance‐mediated oxaliplatin chemoresistance in colorectal cancer. Molecular Carcinogenesis, 63(2), 224-237. https://doi.org/10.1002/mc.23647

Vancouver

Xu Y, Hao J, Chen Q, Qin Y, Qin H, Ren S, et al. Inhibition of the RBMS1/PRNP axis improves ferroptosis resistance‐mediated oxaliplatin chemoresistance in colorectal cancer. Molecular Carcinogenesis. 2024;63(2):224-237. doi:10.1002/mc.23647

BibTeX
@article{Xu2024,
  author = {Xu, Yini and Hao, Jingpeng and Chen, Qiang and Qin, Yafei and Qin, Hong and Ren, Shaohua and Sun, Chenglu and Zhu, Yanglin and Shao, Bo and Zhang, Jingyi and Wang, Hao},
  title = {Inhibition of the RBMS1/PRNP axis improves ferroptosis resistance‐mediated oxaliplatin chemoresistance in colorectal cancer},
  journal = {Molecular Carcinogenesis},
  year = {2024},
  volume = {63},
  number = {2},
  pages = {224--237},
  doi = {10.1002/mc.23647}
}
Kostenlos starten →